Polo-like Kinase 4 inhibition: A strategy for cancer therapy?

Andrew Holland, Don W. Cleveland

Research output: Contribution to journalArticle

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

Original languageEnglish (US)
Pages (from-to)151-153
Number of pages3
JournalCancer Cell
Volume26
Issue number2
DOIs
StatePublished - Aug 11 2014

Fingerprint

Phosphotransferases
Neoplasms
Therapeutics
Clinical Trials
2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Polo-like Kinase 4 inhibition : A strategy for cancer therapy? / Holland, Andrew; Cleveland, Don W.

In: Cancer Cell, Vol. 26, No. 2, 11.08.2014, p. 151-153.

Research output: Contribution to journalArticle

Holland, Andrew ; Cleveland, Don W. / Polo-like Kinase 4 inhibition : A strategy for cancer therapy?. In: Cancer Cell. 2014 ; Vol. 26, No. 2. pp. 151-153.
@article{5270f2f3e020401184760515d9c8347e,
title = "Polo-like Kinase 4 inhibition: A strategy for cancer therapy?",
abstract = "In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.",
author = "Andrew Holland and Cleveland, {Don W.}",
year = "2014",
month = "8",
day = "11",
doi = "10.1016/j.ccr.2014.07.017",
language = "English (US)",
volume = "26",
pages = "151--153",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Polo-like Kinase 4 inhibition

T2 - A strategy for cancer therapy?

AU - Holland, Andrew

AU - Cleveland, Don W.

PY - 2014/8/11

Y1 - 2014/8/11

N2 - In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

AB - In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84905690496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905690496&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2014.07.017

DO - 10.1016/j.ccr.2014.07.017

M3 - Article

C2 - 25117704

AN - SCOPUS:84905690496

VL - 26

SP - 151

EP - 153

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -